Printer Friendly

PHARMOS DRUG DELIVERY SYSTEM OVERCOMES BIOLOGICAL BARRIERS

 KUPIO, Finland, Aug. 30 /PRNewswire/ -- Drugs formulated in Pharmos' novel drug delivery system, Sub-Micron Emulsion (SME) exhibited superior activity compared to commercial counterparts. Dr. Doron Friedman, director of pharmaceutical development at Pharmos Corporation (NASDAQ: PARS), is resenting the results of a study demonstrating increased activity for a number of drugs which were formulated in SME at the "Methods to Overcome Biological Barriers in Drug Delivery," meeting in Kupio, Finland this week.
 Betamethasone dipropionate and several non-steroidal anti- inflammatory drugs formulated in SME demonstrated substantially higher anti-inflammatory activity than their corresponding commercially available products. Additionally, the effect of the local anesthetic, lidocaine, when administered topically in SME, was measured against the cream formulation in healthy volunteers and found to be more effective as well. The unique SME formulation developed by Pharmos improves the delivery of drugs which are sparingly soluble in water (lipophilic) to be formulated in tiny droplets which form a stable and uniform emulsion that increases the drugs' solubility in tissues. According to Dr. Friedman, "These characteristics may reduce the dosing required for activity, thus reducing the incidence of side effects associated with traditionally delivered therapies." A patent application for the SME has been submitted both alone and in combination with a number of studied compounds.
 Pharmos Corporation is engaged in the development of novel pharmaceuticals based on innovative drug delivery technologies targeting diseases of the eye, including glaucoma and ocular inflammation, and the brain, principally stoke and head trauma.
 -0- 8/30/93
 /CONTACT: Stephen R. Streber, president and COO of Pharmos Corporation, 212-838-0087, or Anthony J. Russo, Ph.D. of Noonan-Russo Communications, 212-696-4455, or Donald C. Weinberger of Strategic Growth International, 212-826-9622, both for Pharmos Corporation/
 (PARS)


CO: Pharmos Corporation ST: IN: MTC SU:

LD -- NY008 -- 6932 08/30/93 08:38 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 30, 1993
Words:296
Previous Article:PRICE DROP ANNOUNCED FOR 'ENVIRONMENTAL' RECYCLED PAPER PENCIL
Next Article:INTERMET TO CLOSE LOWER BASIN FOUNDRY
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters